Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 2
1964 2
1981 7
1982 5
1983 6
1984 6
1985 11
1986 7
1987 12
1988 10
1989 21
1990 17
1991 20
1992 17
1993 17
1994 13
1995 27
1996 27
1997 37
1998 47
1999 44
2000 50
2001 77
2002 88
2003 95
2004 129
2005 144
2006 178
2007 211
2008 267
2009 309
2010 350
2011 393
2012 434
2013 584
2014 633
2015 747
2016 819
2017 883
2018 1016
2019 1249
2020 1490
2021 1730
2022 2001
2023 2150
2024 2008
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,510 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for liang x
Search for LiFang X instead (3 results)
Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Zhou M, et al. Among authors: liang x. Lancet. 2019 Sep 28;394(10204):1145-1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24. Lancet. 2019. PMID: 31248666 Free PMC article.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: liang x. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
RNAi therapeutic and its innovative biotechnological evolution.
Weng Y, Xiao H, Zhang J, Liang XJ, Huang Y. Weng Y, et al. Among authors: liang xj. Biotechnol Adv. 2019 Sep-Oct;37(5):801-825. doi: 10.1016/j.biotechadv.2019.04.012. Epub 2019 Apr 26. Biotechnol Adv. 2019. PMID: 31034960 Review.
Coping with salt stress.
Liang X, Jiang C. Liang X, et al. Elife. 2024 Aug 30;13:e101732. doi: 10.7554/eLife.101732. Elife. 2024. PMID: 39212106 Free PMC article.
Molecular Computing and Bioinformatics.
Liang X, Zhu W, Lv Z, Zou Q. Liang X, et al. Molecules. 2019 Jun 26;24(13):2358. doi: 10.3390/molecules24132358. Molecules. 2019. PMID: 31247973 Free PMC article.
16,510 results
You have reached the last available page of results. Please see the User Guide for more information.